Correction of disease-associated exon skipping by synthetic exon-specific activators

Nature Structural Biology

Volumn 10, Issue 2, 2003, Pages 120-125

  Cartegni, Luca ^a   Krainer, Adrian R ^a  

^a Simons Center for Quantitative Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; COMPLEMENTARY RNA; MESSENGER RNA PRECURSOR; SYNTHETIC PEPTIDE;

ALTERNATIVE RNA SPLICING; ARTICLE; BASE PAIRING; COVALENT BOND; EXON; MUTATION; ONCOGENE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN POLYMORPHISM;

ALTERNATIVE SPLICING; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; EXONS; GENES, BRCA1; GENETIC DISEASES, INBORN; HELA CELLS; HUMANS; NERVE TISSUE PROTEINS; POINT MUTATION; RNA-BINDING PROTEINS;

EID: 0037313165     PISSN: 10728368     EISSN: None     Source Type: Journal    
DOI: 10.1038/nsb887     Document Type: Article

References (38)

1. Burge, C.B., Tuschl, T. & Sharp, P.A. Splicing of precursors to messenger RNAs by the spliceosome, in The RNA World II (eds. Gesteland, R.F., Cech, T.R. & Atkins, J.F.) 525-560 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor; 1999).
2. Cartegni, L., Chew, S.L. & Krainer, A.R. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat. Rev. Genet. 3, 285-298 (2002).
3. Maniatis, T. & Tasic, B. Alternative pre-mRNA splicing and proteome expansion in metazoans. Nature 418, 236-243 (2002).
4. Graveley, B.R. Sorting out the complexity of SR protein functions. RNA 6, 1197-1211 (2000).
5. Zhu, J., Mayeda, A. & Krainer, A.R. Exon identity established through differential antagonism between exonic splicing silencer-bound hnRNP A1 and enhancer-bound SR proteins. Mol. Cell 8, 1351-1361 (2001).
6. Krawczak, M., Reiss, J. & Cooper, D.N. The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum. Genet. 90, 41-54 (1992).
7. Ars, E. et al. Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. Hum. Mol. Genet. 9, 237-247 (2000).
8. Teraoka, S.N. et al. Splicing defects in the ataxia-telanglectasia gene, ATM: underlying mutations and consequences. Am. J. Hum. Genet. 64, 1617-1631 (1999).
9. Sierakowska, H., Gorman, L., Kang, S.H. & Kole, R. Antisense oligonucleotides and RNAs as modulators of pre-mRNA splicing. Methods Enzymol. 313, 506-521 (2000).
10. Lacerra, G. et al. Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc. Natl. Acad. Sci. USA 97, 9591-9596 (2000).
11. Friedman, K.J. et al. Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides. J. Biol. Chem. 274, 36193-36199 (1999).
12. Taylor, J.K., Zhang, Q.Q., Wyatt, J.R. & Dean, N.M. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat. Biotechnol. 17, 1097-1100 (1999).
13. Wilton, S.D. et al. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul. Disord. 9, 330-338 (1999).
14. Epstein, P.M. Antisense inhibition of phosphodiesterase expression. Methods 14, 21-33 (1998).
15. Celotto, A.M. & Graveley, B.R. Exon-specific RNAi: a tool for dissecting the functional relevance of alternative splicing. RNA 8, 718-724 (2002).
16. Nakai, K. & Sakamoto, H. Construction of a novel database containing aberrant splicing mutations of mammalian genes. Gene 141, 171-177 (1994).
17. Graveley, B.R. & Maniatis, T. Arginine/serine-rich domains of SR proteins can function as activators of pre-mRNA splicing. Mol. Cell. 1, 765-771 (1998).
18. Zhu, J. & Krainer, A.R. Pre-mRNA splicing in the absence of an SR protein RS domain. Genes Dev. 14, 3166-3178 (2000).
19. Cazalla, D. et al. Nuclear export and retention signals in the RS domain of SR proteins. Mol. Cell. Biol. 22, 6871-6882 (2002).
20. Nielsen, P.E. Antisense properties of peptide nucleic acid. Methods Enzymol. 313, 156-164 (2000).
21. Pooga, M. et al. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol. 16, 857-861 (1998).
22. Sazani, P. et al. Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res. 29, 3965-3974 (2001).
23. Tyler, B.M. et al. Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression. Proc. Natl. Acad. Sci. USA 96, 7053-7058 (1999).
24. Liu, H.X., Cartegni, L., Zhang, M.Q. & Krainer, A.R. A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat. Genet. 27, 55-58 (2001).
25. Mazoyer, S. et al. A BRCA1 nonsense mutation causes exon skipping. Am. J. Hum. Genet. 62, 713-715 (1998).
26. Cartegni, L. & Krainer, A.R. Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat. Genet. 30, 377-384 (2002).
27. Graveley, B.R., Hertel, K.J. & Maniatis, T. A systematic analysis of the factors that determine the strength of pre-mRNA splicing enhancers. EMBO J. 17, 6747-6756 (1998).
28. Jablonka, S., Rossoll, W., Schrank, B. & Sendtner, M. The role of SMN in spinal muscular atrophy. J. Neurol. 247 (Suppl. 1), 137-142 (2000).
29. Monani, U.R. et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum. Mol. Genet. 8, 1177-1183 (1999).
30. Lorson, C.L., Hahnen, E., Androphy, E.J. & Wirth, B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. USA 96, 6307-6311 (1999).
31. Hofmann, Y., Lorson, C. L., Stamm, S., Androphy, E.J. & Wirth, B. Htra2-β1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proc. Natl. Acad. Sci. USA 97, 9618-9623 (2000).
32. Young, P.J. et al. SRp30c-dependent stimulation of survival motor neuron (SMN) exon 7 inclusion is facilitated by a direct interaction with hTra2β1. Hum. Mol. Genet. 11, 577-587 (2002).
33. Andreassi, C. et al. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum. Mol. Genet. 10, 2841-2849 (2001).
34. Chang, J.G. et al. Treatment of spinal muscular atrophy by sodium butyrate. Proc. Natl. Acad. Sci. USA 98, 9808-9813 (2001).
35. Zhang, M.L., Lorson, C.L., Androphy, E.J. & Zhou, J. An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA. Gene Ther. 8, 1532-1538 (2001).
36. Miyajima, H., Miyaso, H., Okumura, M., Kurisu, J. & Imaizumi, K. Identification of a cis-acting element for the regulation of SMN exon 7 splicing. J. Biol. Chem. 277, 23271-23277 (2002).
37. Lim, S.R. & Hertel, K.J. Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3′ splice site pairing. J. Biol. Chem. 276, 45476-45483 (2001).
38. Wagner, E.J. & Garcia-Blanco, M.A. Polypyrimidine tract binding protein antagonizes exon definition. Mol. Cell. Biol. 21, 3281-3288 (2001).